Blood
Articles in this Issue
Modulation of the lipid metabolism in macrophages through chaperone-mediated autophagy in primary immune thrombocytopenia
Abstract Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by thrombocytopenia and bleeding episodes. Ma...
Real-world utilization of bispecific antibodies for treatment of diffuse large B-cell lymphoma (DLBCL) in the US community oncology setting
Abstract BACKGROUND DLBCL is the most common B-cell non-Hodgkin lymphoma in adults, with first-line therapy curing appr...
Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States
Abstract Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by the uncontrolled excessive production of red...
Predictors of 90-day mortality in elderly and unfit AML patients treated with single-agent hypomethylating agents or in combination with venetoclax
Abstract Background: Hypomethylating agents (HMAs) alone or in combination with venetoclax (VEN) offer a lower-intensity...
Safety and efficacy of ten years of hydroxyurea treatment for young children with sickle cell anemia in Uganda
Abstract Introduction. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM, NCT01976416) was a randomized placebo-controlled...
Multiomic dissection of immune-privileged DLBCL reveals divergent immune subtypes in testicular and primary central nervous system lymphoma
Abstract Introduction Diffuse large B-cell lymphomas (DLBCL) arising in immune-privileged sites such as the testis and central nervous syste...
Sequential BCMA and GPRC5D CAR-T cell therapy combined with an optimizing bridging regimen for Relapsed/Refractory multiple myeloma with bulky/extensive extramedullary disease: A synergistic integration approach
Abstract Background: Relapsed/refractory multiple myeloma (RRMM) with bulky/extensive extramedullary disease (EMD) represents a major clinic...
Hepatic plasminogen lowering with a galnac-conjugated siRNA reduces plasmin generation and fibrinolysis but has no effect on thrombin generation in rats and mice
Abstract Introduction: Plasminogen (PLG) is primarily liver-derived and plays a key role in fibrinolysis. Antifibrinolytics, such as tranexa...
Prevalence and management of iron deficiency in patients with bleeding disorders: A single-center, retrospective cohort study
Abstract Background: Iron deficiency (ID) is the most common micronutrient deficiency in the world. Yet, it is frequentl...
Raising hemoglobin level with erythropoietin improves cerebral but not muscle tissue oxygenation in patients with sickle cell disease
Abstract Background In sickle cell disease (SCD), chronic anemia impairs tissue oxygen (O2) delivery, causing hypoxia, microvascular occlusi...
Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib
Abstract Background: Olutasidenib is a potent, selective, oral inhibitor of mutated IDH1 (mIDH1) approved for the treatment of relapsed or re...
Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm
Abstract Introduction: Chronic lymphocytic leukemia (CLL) and myeloproliferative neoplasms (MPN) have a higher rate of co-occurrence than ex...
Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma
Abstract Introduction: In the phase 3, open-label, randomized DREAMM-7 trial (NCT04246047) in patients (pts) with relapsed/refractory multip...
Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma
Abstract Introduction: Talquetamab (tal), a GPRC5D-targeting bispecific antibody (bsAb), is approved for treatment of relapsed/refractory mu...
High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia
Abstract INTRODUCTION: Mutations in Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11) occur in ~8% of Acute Myelogenous Leukemia (A...
Impact of tyrosine kinase inhibitors on estimated glomerular filtration rate in chronic myeloid leukemia patients
Abstract Abstract: Introduction Tyrosine kinase inhibitors (TKIs) are the cornerstone of chronic myeloid leukemia (CML) treatment. While nep...
A phase 1b/2a study of CTO1681 for the prevention of cytokine release syndrome in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy
Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has become an established modality in patients with high-risk B-cell mal...
Access to diagnostics, therapies, and advanced care for lymphoma in Latin America: A multicenter, survey-based study
Abstract Background: The management of lymphomas has been revolutionized by the integration of advanced diagnostics, immunochemotherapy, tar...
Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT
Abstract Background: Secondary AML (sAML) is characterized by a unique cytogenetic and mutational profile that dictates inferior outcomes. A...
Navigating triple therapy in a high-risk cardiac patient with a covered stent and embolic stroke: A case report
Abstract Introduction: Covered stents such as the newly emerging FDA approved papyrus stent plays a pertinent role in the management of coro...
IFN-γ drives long-term bone marrow niche dysfunction following chemotherapy
Abstract Since their introduction in the 1960s, chemotherapy agents have remained a cornerstone of treatment for hematopoietic malignancies....
Prevalence and demographics of autoimmune hemolytic anemia in the United States
Abstract Background: Autoimmune hemolytic anemia (AIHA) is a condition in which the immune system erroneously attacks and damages red blood...
Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel
Abstract Introduction: Axi-cel, an autologous anti-CD19 CAR T-cell therapy has shown high and durable response rates and a manageable safety...
Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study
Abstract Hepatitis B virus (HBV) reactivation represents a potential complication in immunocompromised patients carrying occult B infection...
Multi-omics single-cell spatial profiling of paediatric and adult acute myeloid leukaemia links spatial organization, molecular genetics and microenvironmental interactions
Abstract While acute myeloid leukaemia (AML) urgently requires novel treatment strategies, immunotherapy has so far shown limited efficacy,...